The value of bone marrow scintigraphy using 99mTc monoclonal antigranulocyte antibodies in complement to bone scintigraphy in detecting bone metastases from primary breast cancer

This prospective study evaluates bone marrow scintigraphy (BMS) in detecting bone metastases from primary breast cancer when performed in complement to conventional bone scan (BS). Sixty women predominantly with low-stage disease underwent BS followed by BMS within 1-35 days using BW250/183 antigranulocyte antibodies. A receiver operating characteristic (ROC) analysis was performed to compare BS to BS+BMS on a patient-by-patient basis using a ‘gold standard’ composed of subsequent computed tomography, magnetic resonance imaging, X-ray or BS examinations and at least a 12 month follow-up. Metastases were present in eight out of 60 patients (13%). Specificity was improved by BS+BMS compared to BS alone (90%, 65%) as well as positive predictive value (62%, 27%), accuracy (87%, 72%), positive (10.4, 2.4) and negative (0.20, 0.00) likelihood ratios. Sensitivity (100%, 88%) and negative predictive value (100%, 97%) were similar for BMS+BS and BS alone. As a result of BMS, clinical management was modified in 15 patients (25%). In conclusion, BMS supplements BS by improving specificity, positive predictive value and accuracy in detecting breast cancer bone metastases. The ROC curves show improved specificity for BS+BMS at the same sensitivity compared to BS alone. Consequently, BMS may be useful in low-stage subjects with positive or equivocal BS for metastases.

[1]  J. Mckillop,et al.  The Bone Scan in Metastatic Disease , 1991 .

[2]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[3]  E. Moser,et al.  Comparative detectability of bone metastases and impact on therapy of magnetic resonance imaging and bone scintigraphy in patients with breast cancer. , 2001, European journal of radiology.

[4]  I. Fogelman,et al.  The role of positron emission tomography in the management of bone metastases , 2000, Cancer.

[5]  S. Reske.  Recent advances in bone marrow scanning , 2005, European Journal of Nuclear Medicine.

[6]  Y. Bang,et al.  Technetium-99m-labeled antigranulocyte antibody bone marrow scintigraphy. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[7]  S. Reske,et al.  RADIOIMMUNOIMAGING FOR DIAGNOSIS OF BONE MARROW INVOLVEMENT IN BREAST CANCER AND MALIGNANT LYMPHOMA , 1989, The Lancet.

[8]  B. Smith.  Approaches to breast-cancer staging. , 2000, The New England journal of medicine.

[9]  S. Yasuda,et al.  Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with 99Tcm-MDP bone scintigraphy , 2001, Nuclear medicine communications.

[10]  T. Dimpfl,et al.  Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. , 2000, The New England journal of medicine.

[11]  H. Schirrmeister,et al.  Early detection and accurate description of extent of metastatic bone disease in breast cancer with fluoride ion and positron emission tomography. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Z Kusić,et al.  Bone marrow immunoscintigraphy for the detection of skeletal metastases in patients with breast cancer. , 1999, Nuclear medicine communications.

[13]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[14]  R. Rubens,et al.  Reappraisal of the baseline bone scan in breast cancer. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[15]  I. Carrió,et al.  Radioimmune imaging of bone marrow in patients with suspected bone metastases from primary breast cancer. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.

[17]  Jacques Ferlay,et al.  Estimating the world cancer burden: Globocan 2000 , 2001, International journal of cancer.

[18]  S. Reske,et al.  Bone marrow immunoscintigraphy compared with conventional bone scintigraphy for the detection of bone metastases. , 1993, Acta oncologica.

[19]  M. Estorch,et al.  Antigranulocyte Antibody Bone Marrow Scans in Cancer Patients With Metastatic Bone Superscan Appearance , 1994, Clinical nuclear medicine.

[20]  U. Cremerius,et al.  The present role of bone marrow scintigraphy , 1999, European Journal of Nuclear Medicine.

[21]  M. Greiner,et al.  Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests. , 2000, Preventive veterinary medicine.

[22]  M. Zweig,et al.  Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. , 1993, Clinical chemistry.

[23]  H. Mouridsen,et al.  Clinical and radiologic characteristics of bone metastases in breast cancer , 1987, Cancer.

[24]  P. Pattynama,et al.  Receiver operating characteristic (ROC) analysis: basic principles and applications in radiology. , 1998, European journal of radiology.

[25]  P. Leyvraz,et al.  Immunoscintigraphy with antigranulocyte monoclonal antibodies for the diagnosis of septic loosening of hip prostheses , 1995, European Journal of Nuclear Medicine.